Collaborations & Alliances

Mosaic Therapeutics In-Licenses Oncology Programs from Astex

Mosaic plans to develop proprietary, targeted combination products supported by proprietary biomarkers to realize the full potential of the assets.

Author Image

By: Charlie Sternberg

Associate Editor

Mosaic Therapeutics Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies for patients, has in-licensed two clinical-stage oncology programs from Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd. Mosaic has identified proprietary combinations incorporating the licensed products and their targets and this agreement gives Mosaic the exclusive rights to develop those combination products for patien...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters